KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Obligations AnnualCost Of SalesDistribution Revenue By SegmentDistribution Revenue By Segment AnnualEmployee StatisticsEurope Revenue By CategoryEurope Revenue By Category AnnualFacility Count By RegionGross Margin %Gross Margin By Segment %Gross ProfitGross Profit By SegmentIncome Before Income Taxes By RegionInternational Markets Revenue By CategoryInternational Markets Revenue By Category AnnualInventories BreakdownLicensing Arrangements Revenue By SegmentLicensing Arrangements Revenue By Segment AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %North America Revenue By CategoryNorth America Revenue By Category AnnualOpex As A % Of RevenueOPEX SegregationOther Revenue By SegmentOther Revenue By Segment AnnualPharmaceutical Manufacturing SitesProperty, Plant And Equipment By Geographical LocationProperty, Plant & Equipment BreakdownRevenue By Businesss Vertical AnnualRevenue By Businesss Vertical Annual %Revenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By CustomerRevenue By Customer %Revenue By Major ProductsRevenue By Major Products %Revenue By Major Products AnnualRevenue By Major Products Annual %Revenue By Region AnnualRevenue By Region Annual %Revenue By SegmentRevenue By Segment %Sale Of Goods Revenue By SegmentSale Of Goods Revenue By Segment AnnualSegment ProfitSegment Profit AnnualSegment Profit Margin %Segment Profit Margin Annual %Square Footage By RegionWorkforce Headcount By Region
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Gross Profit (2017 - 2025)

Teva Pharmaceutical Industries filings provide 18 years of Gross Profit readings, the most recent being $2.0 billion for Q1 2026.

  • On a quarterly basis, Gross Profit rose 5.06% to $2.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $9.0 billion, a 10.58% increase, with the full-year FY2025 number at $8.9 billion, up 10.84% from a year prior.
  • Gross Profit hit $2.0 billion in Q1 2026 for Teva Pharmaceutical Industries, down from $2.7 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $2.7 billion in Q4 2025 to a low of $1.6 billion in Q1 2023.
  • Median Gross Profit over the past 5 years was $1.9 billion (2025), compared with a mean of $2.0 billion.
  • Biggest five-year swings in Gross Profit: dropped 13.66% in 2022 and later soared 36.5% in 2023.
  • Teva Pharmaceutical Industries' Gross Profit stood at $1.8 billion in 2022, then surged by 36.5% to $2.4 billion in 2023, then decreased by 12.21% to $2.1 billion in 2024, then rose by 25.22% to $2.7 billion in 2025, then dropped by 25.75% to $2.0 billion in 2026.
  • The last three reported values for Gross Profit were $2.0 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.3 billion (Q3 2025) per Business Quant data.